GELTEQ LTD (GELS) Fundamental Analysis & Valuation
NASDAQ:GELS • AU0000218109
Current stock price
0.7453 USD
+0 (+0.32%)
At close:
0.7071 USD
-0.04 (-5.13%)
After Hours:
This GELS fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. GELS Profitability Analysis
1.1 Basic Checks
- In the past year GELS has reported negative net income.
- In the past year GELS has reported a negative cash flow from operations.
- GELS had negative earnings in each of the past 5 years.
- In the past 5 years GELS always reported negative operating cash flow.
1.2 Ratios
- GELS's Return On Assets of -30.94% is in line compared to the rest of the industry. GELS outperforms 50.78% of its industry peers.
- The Return On Equity of GELS (-42.05%) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -30.94% | ||
| ROE | -42.05% | ||
| ROIC | N/A |
ROA(3y)-21.21%
ROA(5y)-16.14%
ROE(3y)-28.1%
ROE(5y)-20.64%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- Looking at the Gross Margin, with a value of 30.36%, GELS is in line with its industry, outperforming 58.55% of the companies in the same industry.
- GELS's Gross Margin has declined in the last couple of years.
- GELS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 30.36% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.29%
GM growth 5YN/A
2. GELS Health Analysis
2.1 Basic Checks
- GELS does not have a ROIC to compare to the WACC, probably because it is not profitable.
- GELS has more shares outstanding than it did 1 year ago.
- The debt/assets ratio for GELS is higher compared to a year ago.
2.2 Solvency
- GELS has an Altman-Z score of -0.97. This is a bad value and indicates that GELS is not financially healthy and even has some risk of bankruptcy.
- GELS has a Altman-Z score of -0.97. This is comparable to the rest of the industry: GELS outperforms 48.70% of its industry peers.
- A Debt/Equity ratio of 0.00 indicates that GELS is not too dependend on debt financing.
- The Debt to Equity ratio of GELS (0.00) is better than 63.21% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -0.97 |
ROIC/WACCN/A
WACC8.15%
2.3 Liquidity
- A Current Ratio of 0.27 indicates that GELS may have some problems paying its short term obligations.
- With a Current ratio value of 0.27, GELS is not doing good in the industry: 91.19% of the companies in the same industry are doing better.
- GELS has a Quick Ratio of 0.27. This is a bad value and indicates that GELS is not financially healthy enough and could expect problems in meeting its short term obligations.
- Looking at the Quick ratio, with a value of 0.27, GELS is doing worse than 90.16% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.27 | ||
| Quick Ratio | 0.27 |
3. GELS Growth Analysis
3.1 Past
- GELS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -87.41%.
- The Revenue has been growing slightly by 3.95% on average over the past years.
EPS 1Y (TTM)-87.41%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-486.26%
Revenue 1Y (TTM)N/A
Revenue growth 3Y3.95%
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
- No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. GELS Valuation Analysis
4.1 Price/Earnings Ratio
- GELS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. GELS Dividend Analysis
5.1 Amount
- GELS does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
GELS Fundamentals: All Metrics, Ratios and Statistics
0.7453
+0 (+0.32%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-17 2025-11-17
Earnings (Next)06-22 2026-06-22
Inst Owners0.8%
Inst Owner ChangeN/A
Ins Owners41.53%
Ins Owner ChangeN/A
Market Cap7.98M
Revenue(TTM)165.70K
Net Income(TTM)-6.65M
AnalystsN/A
Price TargetN/A
Short Float %2.42%
Short Ratio0.11
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 69.32 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.73 | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.49
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.4
FCFYN/A
OCF(TTM)-0.36
OCFYN/A
SpS0.01
BVpS1.03
TBVpS-0.26
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -30.94% | ||
| ROE | -42.05% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 30.36% | ||
| FCFM | N/A |
ROA(3y)-21.21%
ROA(5y)-16.14%
ROE(3y)-28.1%
ROE(5y)-20.64%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.29%
GM growth 5YN/A
F-Score4
Asset Turnover0.01
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | 387.57% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.27 | ||
| Quick Ratio | 0.27 | ||
| Altman-Z | -0.97 |
F-Score4
WACC8.15%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-87.41%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-486.26%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3Y3.95%
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-94.29%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-405.82%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-415.8%
OCF growth 3YN/A
OCF growth 5YN/A
GELTEQ LTD / GELS Fundamental Analysis FAQ
Can you provide the ChartMill fundamental rating for GELTEQ LTD?
ChartMill assigns a fundamental rating of 1 / 10 to GELS.
What is the valuation status of GELTEQ LTD (GELS) stock?
ChartMill assigns a valuation rating of 0 / 10 to GELTEQ LTD (GELS). This can be considered as Overvalued.
Can you provide the profitability details for GELTEQ LTD?
GELTEQ LTD (GELS) has a profitability rating of 1 / 10.
Can you provide the financial health for GELS stock?
The financial health rating of GELTEQ LTD (GELS) is 1 / 10.